登录 | 注册    关注公众号  
微信公众号
搜索
 > 【TIE2】

TIE2信息

英文名称:TEK receptor tyrosine kinase
中文名称:泰克酪氨酸激酶
靶点别称:EC:2.7.10.1,Endothelial Tyrosine Kinase,Tyrosine-protein kinase receptor TEK,Tunica interna endothelial cell kinase,Angiopoietin-1 receptor,p140 TEK,Tyrosine kinase with Ig and EGF homology domains-2,TEK,TEK Receptor Tyrosine Kinase,Tyrosine-Protein Kinase Receptor TIE-2,TEK Tyrosine Kinase, Endothelial,VMCM1,VMCM,TIE2,Venous Malformations, Multiple Cutaneous And Mucosal,CD202b Antigen,EC 2.7.10.1,CD202B,GLC3E,TIE-2,HTIE2,Receptor, TIE-2,EC 2.7.10
上市药物数量:4
临床药物数量:7
最高研发阶段:批准上市

TIE2产品列表

ACRO质量管理体系
 
评论(1)
TI2-H5255|Human TIE2 Protein, Fc Tag (MALS verified)
  1. 151XXXXXXX5
  2. 0人赞
  3. 本次采购的蛋白抗体,主要用于噬菌体靶点筛选,以及筛选完成后的大量Elisa,为获得优选克隆提供了了方便,还会回购。
  4. 2022-12-09
 

TIE2 分子别名

TIE2,Tie-2,TEK,VMCM, VMCM1,CD202b,Angiopoietin-1 receptor

TIE2 分子背景

Tyrosine-protein kinase that acts as cell-surface receptor for ANGPT1, ANGPT2 and ANGPT4 and regulates angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganization of the actin cytoskeleton, but also maintenance of vascular quiescence. Has anti-inflammatory effects by preventing the leakage of proinflammatory plasma proteins and leukocytes from blood vessels. Required for normal angiogenesis and heart development during embryogenesis. Required for post-natal hematopoiesis. After birth, activates or inhibits angiogenesis, depending on the context. Inhibits angiogenesis and promotes vascular stability in quiescent vessels, where endothelial cells have tight contacts. In quiescent vessels, ANGPT1 oligomers recruit TEK to cell-cell contacts, forming complexes with TEK molecules from adjoining cells, and this leads to preferential activation of phosphatidylinositol 3-kinase and the AKT1 signaling cascades. In migrating endothelial cells that lack cell-cell adhesions, ANGT1 recruits TEK to contacts with the extracellular matrix, leading to the formation of focal adhesion complexes, activation of PTK2/FAK and of the downstream kinases MAPK1/ERK2 and MAPK3/ERK1, and ultimately to the stimulation of sprouting angiogenesis. ANGPT1 signaling triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. Signaling is modulated by ANGPT2 that has lower affinity for TEK, can promote TEK autophosphorylation in the absence of ANGPT1, but inhibits ANGPT1-mediated signaling by competing for the same binding site. Signaling is also modulated by formation of heterodimers with TIE1, and by proteolytic processing that gives rise to a soluble TEK extracellular domain. The soluble extracellular domain modulates signaling by functioning as decoy receptor for angiopoietins. TEK phosphorylates DOK2, GRB7, GRB14, PIK3R1; SHC1 and TIE1.

TIE2 前沿进展

TIE2上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Ponatinib Hydrochloride 盐酸普纳替尼 AP24534 hydrochloride; AP24534-HCL; AP24534 HCl; INCB-84344; AP-24534 批准上市 Ariad Iclusig Japan 急性淋巴细胞白血病, 慢性髓细胞白血病 Otsuka Holdings Co Ltd 2012-12-14 原始细胞危象, 非小细胞肺癌, 双表型急性白血病, 甲状腺瘤, 淋巴瘤, 急性髓细胞样白血病, 慢性髓样白血病, 胃肠道间质瘤, 费城染色体, 甲状腺髓样癌, 常见的胆管肿瘤, 急性淋巴细胞白血病, 慢性髓细胞白血病, 胶质母细胞瘤, 慢性骨髓单核细胞性白血病, 肿瘤, 小细胞肺癌, 肺腺癌, 头颈癌, 实体瘤, 髓系白血病加速期, 白血病, 血液肿瘤 详情
Regorafenib 瑞戈非尼 DAST; BAY-73-4506 批准上市 拜耳 Stivarga, Resihance Mainland China 胃肠道间质瘤 Bayer Pharma Ag 2012-09-27 急性髓细胞样白血病, 肉瘤, 胃泌素瘤, 骨肉瘤, 尤因肉瘤, 结直肠癌, 腹膜癌, 胃肠道间质瘤, 胆道癌, 输卵管癌, 食道腺癌, 腺瘤, 甲状腺瘤, 肺癌, 胸腺瘤, 肝细胞癌, 腺癌, 黑色素瘤, 转移癌, 胃肠道癌症, 生长抑制素瘤, 胰岛细胞癌, 卵巢癌, 肝癌, 血管肉瘤, 食道癌, 胃癌, 肾细胞癌, 直肠癌, 类癌瘤, 胰岛素瘤, 实体瘤, 结肠癌, 肿瘤, 卵巢上皮癌, 胰腺癌, 小细胞肺癌, 胶质母细胞瘤, 尿路上皮癌, 腺样囊性癌, 胰高血糖素瘤 详情
Cabozantinib S-malate 苹果酸卡博替尼 XL-184; BMS-907351 批准上市 Exelixis Inc Cometriq, Cabometyx Japan 肾细胞癌 Takeda 2012-11-29 骨肉瘤, 甲状腺瘤, 神经胶质肉瘤, 结直肠癌, 腹膜癌, 胆道癌, 肝功能衰退, 星形细胞瘤, 乳腺癌, 尤因肉瘤, 淋巴瘤, 腺鳞癌, 透明细胞腺癌, 透明细胞肉瘤, 甲状腺髓样癌, 胆管上皮癌, 前列腺癌, 丛状神经纤维瘤, 尿道癌, 神经内分泌癌, 脑膜瘤, 非小细胞肺癌, 副神经节瘤, 黑色素瘤, 子宫内膜样癌, 甲状腺乳头状瘤, 腺癌, 生殖细胞和胚胎肿瘤, 肝细胞癌, 神经母细胞瘤, 胶质瘤, 急性髓细胞样白血病, 鳞状细胞癌, 子宫内膜癌, 肺癌, 肺泡软组织肉瘤, 子宫肿瘤, 输卵管癌, 类癌瘤, 神经纤维瘤病, 精原细胞瘤, 尿路上皮癌, 胶质母细胞瘤, 肝脏移植排斥, Merkel细胞癌, 肝胚细胞瘤, 疼痛, 嗜铬细胞瘤, 肿瘤, 肾细胞癌, 骨转移, HIV感染, 平滑肌肉瘤, 卵巢癌, 横纹肌肉瘤, 卵巢生殖细胞肿瘤, 肾肿瘤, 肾脏疾病, 肉瘤, 脑癌, 中枢神经系统肿瘤, 肾上腺皮质细胞癌, 滤泡性腺癌, 多发性骨髓瘤, 详情
Ripretinib 瑞派替尼 DCC-2618 批准上市 Deciphera 擎乐, Qinlock United Kingdom 胃肠道间质瘤 Deciphera Pharmaceuticals Llc 2020-05-15 系统性肥大细胞增多症, 肿瘤, 胃肠道间质瘤 详情

TIE2临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
QBH-196 QBH-196 临床一期 沈阳药科大学 实体瘤, 胃癌 详情
AV-001 AV-001 临床二期 Vasomune Therapeutics Inc 呼吸道感染, 肺炎, 新型冠状病毒肺炎, 成人呼吸窘迫综合征, 病毒性肺炎 详情
Trebananib AMG-386; 20060439 临床二期 安进, Takeda Pharmaceutical Co Ltd 输卵管癌, 乳腺癌, 脑癌, 前列腺癌, 肉瘤, 腹膜癌, 结直肠癌, 女性生殖系统癌症, 神经胶质肉瘤, 子宫内膜癌, 腺鳞癌, 肺癌, 子宫肿瘤, 急性髓细胞样白血病, 急性单核细胞白血病, 腺癌, 非小细胞肺癌, 转移癌, 胃肠道癌症, 肿瘤, 实体瘤, 髓样白血病, 急性成红细胞白血病, 肾细胞癌, 转移性上皮癌, 直肠癌, 血管肉瘤, 结肠癌, 卵巢癌, 肾脏疾病, 急性粒单核细胞白血病, 胶质母细胞瘤, 子宫内膜间质肉瘤, 中枢神经系统肿瘤, 神经内分泌瘤, 急性巨核细胞白血病, 少突神经胶质瘤 详情
Sitravatinib IND-155305; MG-516; MG-91516; MGCD-516 临床三期 Mirati Therapeutics Inc 乳腺癌, 肝细胞癌, 胃肠道癌症, 宫颈癌, 非小细胞肺癌, 肺癌, 鳞状细胞癌, 口腔癌, 子宫内膜癌, 食管鳞状细胞癌, 肝功能衰退, 输尿管肿瘤, 肾肿瘤, 脂肪肉瘤, 肺疾病, 葡萄膜黑色素瘤, 三阴性乳腺癌, 尿路上皮癌, 肿瘤, 转移性上皮癌, 头颈部鳞状细胞癌, 肾细胞癌, 胆管癌, 实体瘤 详情
CEP-11981 ESK-981; CEP-11981; SSR-106462; BOL-303213X 临床二期 赛诺菲 肿瘤, 前列腺癌 详情
Gersizangitide AXT-107 临床二期 AsclepiX Therapeutics Inc 糖尿病黄斑水肿, 年龄相关性黄斑变性 详情
Rebastinib Tosylate DP-1919; DCC-2036; DP-1919.TO 临床二期 Deciphera 实体瘤, 慢性髓细胞白血病 详情

消息提示

请输入您的联系方式,再点击提交!

确定